Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn’s Disease

被引：0
|
作者：
Andrew P. Yu
Scott Johnson
Si-Tien Wang
Pavel Atanasov
Jackson Tang
Eric Wu
Jingdong Chao
Parvez M. Mulani
机构：
[1] Analysis Group,
[2] Inc.,undefined
[3] Abbott Laboratories,undefined
来源：
PharmacoEconomics | 2009年 / 27卷
关键词：
Infliximab; Adalimumab; Probabilistic Sensitivity Analysis; Tumour Necrosis Factor Antagonist; Infliximab Maintenance Therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Objective: To determine and compare the cost utilities of the tumour necrosis factor (TNF) antagonists adalimumab and infliximab as maintenance therapies for patients in the US with moderately to severely active Crohn’s disease.
引用
收藏
页码：609 / 621
页数：12
相关论文
共 50 条
  • [31] Maintenance therapy versus episodic therapy with infliximab for Crohn's disease
    Subrata Ghosh
    Nature Clinical Practice Gastroenterology & Hepatology, 2004, 1 : 80 - 81
  • [32] Maintenance therapy with infliximab every 8 weeks is superior to every 12 weeks in maintaining response and remission in pediatric patients with moderately to severely active Crohn's disease
    Hyams, Jeffrey
    Crandall, Wallace
    Kugathasan, Subia
    Griffiths, Anne
    Olson, Allan
    Johanns, Jewel
    Liu, Grace
    Travers, Suzanne
    Heuschkel, Robert
    Markowitz, James
    Cohen, Stanley
    Winter, Harland
    Veereman-Wauters, Gigi
    Ferry, George
    Baldassano, Robert
    GASTROENTEROLOGY, 2006, 130 (04) : A12 - A12
  • [33] PHARMACOKINETICS OF SUBCUTANEOUS INFLIXIMAB INDUCTION AND MAINTENANCE IN MODERATE-TO-SEVERELY ACTIVE CROHN'S DISEASE PATIENTS: WEIGHT MATTERS
    Anjie, Suzanne I.
    Mathot, Ron
    Gecse, Krisztina
    D'Haens, Geert
    GASTROENTEROLOGY, 2024, 166 (05) : S824 - S825
  • [34] COST UTILITY ANALYSIS OF CERTOLIZUMAB PEGOL VERSUS NATALIZUMB MAINTENANCE THERAPY FOR CROHN'S DISEASE
    Wu, B.
    VALUE IN HEALTH, 2010, 13 (03) : A73 - A73
  • [35] Impact of concomitant immunosuppressant use on adalimumab efficacy in children with moderately to severely active Crohn's disease: Results from IMAgINE 1
    Hyams, J.
    Ruemmele, F.
    Colletti, R.
    Kierkus, J.
    Rosh, J.
    Eichner, S.
    Lazar, A.
    Li, Y.
    Thakkar, R. B.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S257 - S258
  • [36] Impact of Concomitant Immunosuppressant Use on Adalimumab Efficacy in Children With Moderately to Severely Active Crohn's Disease: Results From IMAgINE 1
    Hyams, Jeffrey S.
    Ruemmele, Frank
    Colletti, Richard B.
    Kierkus, Jaroslaw
    Rosh, Joel R.
    Eichner, Samantha
    Lazar, Andreas
    Li, Yao
    Thakkar, Roopal
    GASTROENTEROLOGY, 2014, 146 (05) : S214 - S214
  • [37] Impact of concomitant immunosuppressant use on adalimumab efficacy in children with moderately to severely active Crohn's disease: results from IMAgINE 1
    Hyams, J. S.
    Ruemmele, F.
    Colletti, R. B.
    Kierkus, J.
    Rosh, J.
    Eichner, S.
    Lazar, A.
    Li, Y.
    Thakkar, R. B.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S430 - S430
  • [38] Efficacy and safety of adalimumab for the treatment of Japanese patients with moderately to severely active Crohn's disease: Results from a randomized controlled trial
    Hibi, Toshifumi
    Watanabe, Mamoru
    Camez, Anne
    Khan, Mahmudul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S414 - S415
  • [39] Efficacy and safety of infliximab versus adalimumab in the treatment of Crohn's disease: The McGill Experience
    Al-Taweel, T.
    Strohl, M.
    Kopylov, U.
    Paradis-Suprenant, L.
    Almaimany, M.
    Martel, M.
    Bitton, A.
    Afif, W.
    Bessissow, T.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S369 - S369
  • [40] Adalimumab maintains long-term remission in moderately to severely active Crohn's disease after infliximab failure: 1-year follow-up of gain trial
    Panaccione, Remo
    Sandbom, William J.
    D'Haens, Geert
    Enns, Robert A.
    Wolf, Douglas C.
    Lomax, Kathleen G.
    Pollack, Paul F.
    GASTROENTEROLOGY, 2008, 134 (04) : A133 - A134
12345